Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Staphylococcus
NCT ID: NCT02701608
Last Updated: 2021-05-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
324 participants
INTERVENTIONAL
2016-02-29
2024-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A recent survey of practices regarding the management of IE in France showed that a switch from IV to oral antibiotics is feasible, when patients with left-sided Staphylococcus IE are stable after an initial course of IV antibiotic treatment, with or without valvular surgery.
These practices have not been associated with unfavourable outcome, while significantly reducing the duration and cost of hospitalization, the risk of nosocomial infection, and patients' discomfort.
There has been no randomized controlled trial (RCT) in the field of IE over the last 20 years; current guidelines are mostly based on expert advice, in vitro studies, animal experiments, or clinical studies performed before the 90's.
The RODEO 1 project is an unprecedented opportunity to bring back evidence-based medicine in the field of IE.
Most experts acknowledge that the pharmacological PK/PD characteristics of antibiotics such as fluoroquinolones and rifampicin allow a high level of efficacy in the treatment of IE when orally administrated after an IV period of induction.
It's needed to conduct RCTs that clearly demonstrate the clinical non-inferiority of this strategy for multisusceptible staphylococci with a benefit regarding costs.
The RODEO 1 project corresponds to one pragmatic trial assessing the impact of a switch strategy, making it a comparative effectiveness trial that should be able to feed the next revision of IE international guidelines and to change practices in IE management.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Streptococcus
NCT02701595
Resistant Bacteria in Children in France
NCT06036628
Rifampin-free Regimen Versus Rifampin-containing Regimen in the Treatment of Staphylococcal Prosthetic Valve Endocarditis
NCT07345325
Efficacy of a Short-term Sequential Therapy in Non-complicated Catheter Related Bacteremia by Methicillin- Susceptible S.Aureus.
NCT01875263
Staphylococcus Aureus Bacteremia Antibiotic Treatment Options
NCT01792804
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Nationwide, noninferiority, multicenter, randomized, controlled, open-label trials.
Randomisation will only be offered to patients who have received at least 10 days of IV conventional antibiotic treatment of IE, and fulfil the inclusion criteria.
Randomisation will take place between Day 10 and Day 28 after initiation of parenteral antibiotic therapy or valvular surgery, thus ensuring to have at least 14 days of oral therapy in the experimental group.
Patients will be eligible whether they have undergone valvular surgery or not. This will imply that surgery procedure prior to randomisation will be heterogeneous, but randomisation will be stratified on the requirement of valvular surgery as part of the treatment of the current episode of IE or not.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Oral switch treatment
Oral switch to the combination of levofloxacin and rifampicin
Levofloxacin
levofloxacin 500 mg x1/day (for patients ≤70kg) or levofloxacin 750 mg x1/day (for patients \>70kg)
Rifampicin
rifampicin 600mg x1/day (for patients ≤70kg) or rifampicin 900mg x1/day (for patients \>70kg)
Conventional IV treatment according to european guidelines
Conventional IV treatment of staphylococci IE (European guidelines 2015)
Conventional IV treatment of staphylococci IE following European guidelines 2015 including cloxacilline, oxacilline,gentamicine,vancomycine,rifampicine
Conventional IV treatment of staphylococci IE following European guidelines 2015 including cloxacilline, oxacilline,gentamicine,vancomycine,rifampicine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Levofloxacin
levofloxacin 500 mg x1/day (for patients ≤70kg) or levofloxacin 750 mg x1/day (for patients \>70kg)
Rifampicin
rifampicin 600mg x1/day (for patients ≤70kg) or rifampicin 900mg x1/day (for patients \>70kg)
Conventional IV treatment of staphylococci IE following European guidelines 2015 including cloxacilline, oxacilline,gentamicine,vancomycine,rifampicine
Conventional IV treatment of staphylococci IE following European guidelines 2015 including cloxacilline, oxacilline,gentamicine,vancomycine,rifampicine
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* due to one isolate of Staphylococcus sp. (S. aureus or coagulase negative staphylococci, CNS) susceptible to levofloxacin and rifampicin
* in an adult ≥18 year old
* appropriate parenteral antibiotics treatment received for at least 10 days
* in case of valvular surgery, appropriate parenteral antibiotics treatment received for at least 10 days after valvular surgery
* planned duration of antibiotics will extend for at least 14 days at the time of randomisation i.e. a potential switch to oral treatment between Day 10 and Day 28 thus ensuring to have at least 14 days of oral therapy remaining in the experimental group
* apyrexia (temperature \< 38°C) at each time point during the last 48 hours (at least two measures/day) at the time of randomisation
* blood cultures have been sterile for at least 5 days at the time of randomisation
* informed, written consent obtained from patient
* subject covered by or having the rights to French social security
Exclusion Criteria
* glomerular filtration rate \< 50 ml/min/1,73m²
* patient unable or unwilling to take oral treatment (digestive intolerance, significant malabsorption) at the time of randomisation
* expected difficulties regarding compliance with oral antibiotic treatment or follow-up (e.g. severe cognitive impairment, severe psychiatric disease...)
* patient without entourage to support and watch him at discharge
* valvular surgery planned within the next 6 months
* patients with cardiac devices (pace-maker, implantable cardiac defibrillator) and suspected device-related IE (vegetation on the leads) if removal of the device was not performed
* breast feeding or pregnant women, or women on childbearing age without effective contraception
* expected duration of follow-up \< 7 months at the time of randomisation (e.g. expected life expectancy \< 7 months, patient living abroad...)
* past medical history of IE in the last 3 months
* other infection requiring parenteral antibiotic therapy
* taking of an estrogen-progesterone treatment interacting with rifampicin
* patient with contra-indication to oral antibiotics administered in the experimental arm (i.e. fluoroquinolones or rifampicin ) - including anticipated non-manageable drug interactions with rifampicin, and allergy.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Tours
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Louis BERNARD, MD,PHD
Role: PRINCIPAL_INVESTIGATOR
CHRU TOURS
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Service des Maladies infectieuses, Centre Hospitalier du Pays d'Aix
Aix-en-Provence, , France
Service de court séjour gériatrique - EMG, Centre hospitalier d'Alès
Alès, , France
Service de Pathologies infectieuses et tropicales, Hôpital Nord, CHU d'Amiens
Amiens, , France
CHU ANGERS - Service des maladies infectieuses et tropicales
Angers, , France
Service des Maladies infectieuses et Tropicales, Hôpital Jean Minjoz, CHU de Besançon
Besançon, , France
Service de Maladies infectieuses et tropicales, Hôpital Avicenne, APHP
Bobigny, , France
Service de Réanimation médicale, Hôpital St André, CHU de Bordeaux
Bordeaux, , France
Service de Médecine interne, Hôpital Ambroise Paré, APHP
Boulogne-Billancourt, , France
Service de Maladies infectieuses, Hôpital de la Cavale Blanche
Brest, , France
Service de Cardiologie, Hôpitall Louis Pradel, Hôpitaux Est, Hospices Civils de Lyon
Bron, , France
Service Maladies Infectieuses et tropicales, Hôpital Côte de Nacre, CHU de Caen
Caen, , France
Service de Maladies infectieuses et tropicales, médecine interne, CH de Chambéry
Chambéry, , France
Service des maladies infectieuses et tropicales, Hôpital G. Montpied, CHU de Clermont-Ferrand
Clermont-Ferrand, , France
APHP Henri-Mondor - Service des maladies infectieuses et tropicales
Créteil, , France
Département d'infectiologie, Complexe Bocage, Hôpital d'enfants, CHU de Dijon
Dijon, , France
Service de Médecine interne polyvalente et neurologique CH de Douai
Douai, , France
Service de Médecine aigue spécifique, Hôpital Raymond Poincaré, APHP
Garches, , France
Service de Médecine post-urgence, infectiologie, Site de la Roche sur Yon, CHD Vendée
La Roche-sur-Yon, , France
Service de Médecine infectieuse, Hôpital Nord Michallon, CHU de Grenoble
La Tronche, , France
Service de Maladies infectieuses et tropicales, et pathologie VIH
Le Chesnay, , France
APHP BICETRE - Service des maladies infectieuses et tropicales
Le Kremlin-Bicêtre, , France
Service des Maladies infectieuses et tropicales, CH Le Mans
Le Mans, , France
Unité médicale d'infectiologie, Hôpital Huriez, CHU de Lille
Lille, , France
Service de Maladies Infectieuses et tropicales, Hôpital Dupuytren, CHU de Limoges
Limoges, , France
Clinique de la Sauvegarde
Lyon, , France
Service de Maladies infectieuses, Hôpital Gui de CHauliac, CHU de Montpellier
Montpellier, , France
Service de Maladies infectieuses et tropicales, Hôpital Hôtel Dieu, CHU Nantes
Nantes, , France
Service d'Infectiologie, Hôpital de l'Archet, CHU de Nice
Nice, , France
Service des Maladies infectieuses, CH de Niort
Niort, , France
Service des Maladies Infectieuses et Tropicales, Hôpital Carémeau, CHU de Nîmes
Nîmes, , France
Service de Maladies infectieuses et tropicales, Hôpital de la Source, CHR Orléans
Orléans, , France
APHP St Antoine
Paris, , France
Service de Microbiologie, Hôpital Européen Georges Pompidou, APHP
Paris, , France
Service de Maladies infectieuses et tropicales, Hôpital Necker, APHP
Paris, , France
Service de Maladies infectieuses, parasitaires et tropicales, Hôpital Bichat, APHP
Paris, , France
Institut Mutualiste Montsouris - Service de médecine interne
Paris, , France
CH PAU - Service de Médecine interne et Maladies infectieuses
Pau, , France
Service des Maladies infectieuses et tropicales, CH de Perpignan
Perpignan, , France
Service de Médecine interne, maladies infectieuses et tropicales, CHU de Poitiers
Poitiers, , France
Infectiologie, médecine interne et médecine des voyages, CH d'Annecy
Pringy, , France
CH QUIMPER - Service d'infectiologie
Quimper, , France
Service de Médecine interne, maladies infectieuses, immunologie clinique, Hôpital R. Debré, CHU de Reims
Reims, , France
Service des maladies infectieuses et réanimation médicale, Hôpital Pontchaillou, CHU de Rennes
Rennes, , France
Service des Maladies infectieuses et tropicales, Hôpital Charles Nicolle, CHU de Rouen
Rouen, , France
Service des Maladie infectieuses et tropicales, Hôpital d'instruction des armées Bégin
Saint-Mandé, , France
CHU St Etienne - Service des maladies infectieuses et tropicales
Saint-Priest-en-Jarez, , France
Service des maladies respiratoires et infectieuses, CH de St Malo
St-Malo, , France
Service des Maladies infectieuses et tropicales, Hôpital de Purpan, CHU de Toulouse
Toulouse, , France
CHU Toulouse (Rangueil) Service de Cardiologie
Toulouse, , France
Service Universitaire des Maladies Infectieuses et du voyageur, CH de Tourcoing
Tourcoing, , France
Service de Médecine interne et maladies infectieuses, Hôpital Bretonneau, CHU de Tours
Tours, , France
Service de Maladies infectieuses et tropicales, Hôpitaux de Brabois, CHU de Nancy
Vandœuvre-lès-Nancy, , France
Consultation de Médecine Interne, maladies infectieuses et tropicales, CH intercommunal de Villeneuve St Georges
Villeneuve-Saint-Georges, , France
Médipôle Lyon Villeurbanne
Villeurbanne, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Lemaignen A, Bernard L, Tattevin P, Bru JP, Duval X, Hoen B, Brunet-Houdard S, Mainardi JL, Caille A; RODEO (Relais Oral Dans le traitement des Endocardites a staphylocoques ou streptOcoques) and AEPEI (Association pour l'Etude et la Prevention de l'Endocardite Infectieuse) study groups. Oral switch versus standard intravenous antibiotic therapy in left-sided endocarditis due to susceptible staphylococci, streptococci or enterococci (RODEO): a protocol for two open-label randomised controlled trials. BMJ Open. 2020 Jul 14;10(7):e033540. doi: 10.1136/bmjopen-2019-033540.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RODEO 1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.